Design flaws plague many animal-based drug studies, researchers say

January 22, 2014
Design flaws plague many animal-based drug studies, researchers say
They include poorly organized trials and no follow-up on side effects from the medicines tested.

(HealthDay)—Many pharmaceutical studies in animals that lead to trials in humans have serious design flaws, a new study suggests.

Researchers analyzed 63 animal studies of popular cholesterol-lowering drugs called statins—drugs such as Crestor, Lipitor and Zocor. Some of the studies were funded by the government and other non-industry sources, while others were paid for by drug companies.

Numerous were found in the studies regardless of who funded them, found the researchers, led by Lisa Bero, a pharmacologist at the University of California, San Francisco, School of Pharmacy.

For example, were not randomly divided into treatment or placebo groups—a requirement of high-quality clinical trials—in about half the studies, the researchers said.

And in about half the studies, the animals were identifiable to the person giving them the drug or placebo, Bero's team found. That's a violation of a research practice called "blinding," in which researchers do not know which animal or human got the treatment and which did not.

In addition, many of the studies did not explain the criteria for including or excluding animals, the researchers said. Many also did not properly explain treatment changes made among groups of animals that were being given the drugs.

Finally, the harmful side effects—the "adverse events"—of the drugs were not investigated.

"Not a single animal study we looked at assessed adverse events following the statin intervention," Bero said in a university news release.

"As toxicity data from animal studies must be submitted to regulatory authorities before a compound can proceed to testing in humans, it is surprising that so little data on harm appears in the published scientific literature," she said.

Conclusions of all the studies tended to be favorable, the researchers said. But compared to studies funded by government and other nonindustry sources, studies funded by were more likely to present favorable conclusions—even when the data was less favorable.

These findings highlights the role of "spin" in communicating study findings, Bero said.

The study was published online Jan. 21 in the journal PLoS Biology.

Explore further: Bias pervades the scientific reporting of animal studies

More information: The U.S. Food and Drug Administration explains how drugs are developed and approved.

Related Stories

Bias pervades the scientific reporting of animal studies

July 17, 2013
A new study published in the open access journal PLOS Biology suggests that the scientific literature could be compromised by substantial bias in the reporting of animal studies, and may be giving a misleading picture of ...

Industry sponsorship leads to bias in reported findings of clinical trials

December 11, 2012
Studies reporting the results of industry sponsored clinical trials present a more favourable picture of the effects of drugs and medical devices than those reporting on non-industry sponsored trials, according to a new Cochrane ...

Study examines drug labeling and exposure in infants

December 9, 2013
Federal legislation encouraging the study of drugs in pediatric patients has resulted in very few labeling changes that include new infant information, according to a study by Matthew M. Laughon, M.D., M.P.H., of the University ...

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.